logo
ResearchBunny Logo
Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy

Medicine and Health

Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy

J. Yi, O. Tavana, et al.

Exciting discoveries in cancer therapy show that targeting the USP2-VPRBP axis can effectively reactivate p53 and reduce toxicity compared to traditional Mdm2 inhibitors. This innovative approach, explored by authors Jingjie Yi, Omid Tavana, Huan Li, Donglai Wang, Richard J. Baer, and Wei Gu, demonstrates complete tumor regression in wild-type p53 tumors with the combination of a USP2 inhibitor and anti-PD1 antibody.

00:00
00:00
Playback language: English
Abstract
Mdm2 inhibitors, while effective in reactivating p53 in pre-clinical models, show serious toxicity in clinical trials. This study identifies the USP2-VPRBP axis as a crucial regulator of p53 and PD-L1. VPRBP, a p53 repressor, is stabilized by USP2. The combination of a USP2 inhibitor and anti-PD1 antibody leads to complete tumor regression in wild-type p53 tumors, without the toxicity observed with Mdm2 inhibitors. This USP2/VPRBP targeting strategy offers a promising p53-based cancer therapy.
Publisher
Nature Communications
Published On
Apr 06, 2023
Authors
Jingjie Yi, Omid Tavana, Huan Li, Donglai Wang, Richard J. Baer, Wei Gu
Tags
Mdm2 inhibitors
p53 reactivation
USP2-VPRBP axis
tumor regression
cancer therapy
toxicity reduction
anti-PD1 antibody

Related Publications

Explore these studies to deepen your understanding of the subject.

Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer
Medicine and Health

Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer

Y. Iwatate, I. Hoshino, et al.

Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges
Engineering and Technology

Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges

R. P. Singh, A. Natarajan, et al.

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study
Medicine and Health

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study

J. An, X. Li, et al.

CD317 maintains proteostasis and cell survival in response to proteasome inhibitors by targeting calnexin for RACK1-mediated autophagic degradation
Medicine and Health

CD317 maintains proteostasis and cell survival in response to proteasome inhibitors by targeting calnexin for RACK1-mediated autophagic degradation

J. Cheng, G. Zhang, et al.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny